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Abstract
Purpose: To identify barriers and facilitators to opioid use treatment and recovery
services among pregnant and nonpregnant women who misuse opioids.
Background: Over 130 Americans die daily after overdosing on opioids. Women have
not been immune from opioid use disorders (OUDs), with a 4-fold increase from 19992010. The prevalence of opioid use among pregnant women increased from 1.5 per 1,000
hospital deliveries to 6.5. Although the annual National Surveys on Drug Use and Health
(NSDUH) has provided information on risk factors for OUD related to socioeconomic
and demographic factors, no studies using this data have identified barriers to opioid use
treatment among pregnant and nonpregnant women.
Specific aims: (1) describe demographic characteristics (age, race/ethnicity, education,
marital status, health insurance, employment, income, geographic location, and treatment
setting), clinical characteristics (health status, mental health status, and substance use),
and opioid use treatment and recovery services among pregnant and nonpregnant women
who misuse opioids, (2) examine the relationships among demographic characteristics,
clinical characteristics, perceived need for treatment, and facilitators/barriers to opioid
use treatment and recovery services among pregnant and nonpregnant women who
misuse opioids, (3) identify factors associated with increased odds of opioid use
treatment among pregnant women who misuse opioids.
Method: A cross-sectional correlational study using 2016 to 2018 NSDUH data. Sample
included 122 pregnant and 3305 nonpregnant women who misused opioids. Descriptive
statistics and bivariate analysis examined the variables between the groups of women.

Results: The sample (n=3427) women who misused opioids, 67.3% were 18-25 years old
and 64.8% were non-Hispanic white. Both groups worked full time (36%), earned
between $20,000 and $49,000 per year (34%), and never married (66.5%). Significant
associations were noted among; age (χ2=25.406, p=<0.001), race/ethnicity (LR=17.721,
p=<0.007), geographic location (χ2=7.585, p=<0.023), health insurance (LR=13.909,
p=<0.016), tobacco use within the past year (χ2=7.058, p=008), and alcohol use within
the past month (χ2=76.783, p=<0.001).
Implications: Study findings indicate 3.3% of pregnant women and 1.8% of nonpregnant
women who misuse opioids perceive they have a need to obtain treatment. Further
research is necessary to explore the construct of perceived need in this population, as well
as, strategies to increase engagement.

Copyright © 2020 Loralie Woods
All rights reserved
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Chapter Ⅰ
Introduction
Over 130 Americans die daily after overdosing on opioids (Centers for Disease
Control and Prevention (CDC, 2018a). In 2016 alone, over 42,000 Americans died due to
opioid overdose and for each of these fatal overdoses, there were more than 30 nonfatal
overdoses (CDC, 2017a). One out of six overdose deaths in the United States from 19992014 resulted from an opioid overdose (Rudd, 2016). The economic burden of
prescription opioid misuse in the United States is estimated at $78.5 billion a year
(Florence, Zhou, Luo, & Xu, 2016). This includes the cost of healthcare, lost
productivity, addiction treatment, and criminal justice involvement.
From 1999 to 2010 opioid use among women increased 4-fold (CDC, 2018b), and
pregnant women have not been immune from opioid use disorders (OUDs). The
prevalence of opioid use among pregnant women increased from 1.5 to 8 per 1,000
hospital deliveries (Wachman, Schiff, & Silverstein, 2018). This rise in OUD in
pregnancy has resulted in an increase in fetal and neonatal mortality and morbidity (CDC,
2018b). Opioid use can result in placental abruption, stillbirth, or neonatal abstinence
syndrome (NAS) (Maeda, Bateman, Clancy, Creanga, & Leffert, 2014). From 2004 to
2014, the incidence of (NAS) in the United States increased 433%. Sadly, a baby is born
every 15 minutes in the US with NAS (Jilani et al., 2019). The estimated hospital cost is
1.5 billion (Patrick et al, 2015).
According to the National Survey of Substance Abuse Treatment Services (NSSATS) only 46% of substance use treatment programs provided special programs or
groups for adult women and only 21% offered programs or groups specially for pregnant
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or postpartum women (SAMHSA, 2016). The reasons for this disparity are not well
understood; however, the maternal and neonatal consequences of not receiving treatment
for OUDs is well known.
Maternal and Neonatal Adverse Outcomes Related to OUDs
Withdrawal from opioids can cause significant physiological disruption, leading
to poor outcomes for the mother and infant (Maeda et al., 2014). In addition to dying
from an opioid overdose, having an OUD may place a pregnant woman at greater risk of
experiencing violence, contracting Hepatitis C and Human Immunodeficiency Virus
(HIV), or other sexually transmitted infections (Sutter, Gopman, & Leeman, 2017).
Furthermore, opioid use can result in placental abruption, stillbirth, or (NAS) (Maeda et
al., 2014). NAS is a clinical condition in which a neonate experiences various levels of
irritability, temperature dysregulation, poor feeding, failure to thrive, and seizures due to
the abrupt discontinuation of intrauterine exposure to opioids used by the mother during
pregnancy (Kaltenbach et al., 2012; Kocherlakota, 2014). This condition may last for up
to 10 weeks after delivery and may necessitate a prolonged hospital stay (Patrick et al.,
2015). To prevent these adverse outcomes and provide appropriate treatment and
services, it is imperative to understand factors that influence pregnant woman with an
OUD to seek treatment.
Barriers to Seeking Treatment for OUDs
The National Institute on Drug Abuse (2018) defines addiction to substances as a
chronic disease that can be managed and treated successfully. Regrettably, pregnant
women with OUD face numerous barriers to treatment, including limited access to
gender specific treatment, stigma, and fear of legal consequences (Saia et al., 2016).
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Many women who are in caregiving roles often will not seek treatment or do not
complete treatment because they are unable to manage their caregiving responsibilities
and participate in treatment programs at the same time (Saia et al., 2016). Other concerns
include fear their children will be removed from their custody (Angelotta, Weiss,
Angelotta, & Friedman, 2016). The National Survey on Drug Use and Health (NSDUH)
is an annual survey sponsored by SAMSHA, an agency of the UD Department of Health
and Human Services. Since 1971, data were collected on substance use patterns and
behaviors among non-institutionalized US civilians in order to inform public policy and
monitor substance use trends (NSDUH, 2018a). This survey contains questions on the
barriers to seeking opioid use treatment; however, no studies thus far address barriers
among pregnant and no-pregnant women seeking treatment for opioid misuse. Limited
reports and research using the NSDUH among pregnant and nonpregnant women with
OUDs focus on the demographic and clinical characteristics of this population and
predictors of opioids use.
NSDUH data from 2005 to 2014 of non-medical opioid use among pregnant
women found a prevalence of 5% (Kozhimannil, Graves, Levy, & Patrick, 2017).
Depression and anxiety were major risk factors for non-medical opioid use indicating two
potential screening strategies for prevention. Kozhimannil et al. (2017) also found prior
alcohol, tobacco, and marijuana use independently predicted non-medical opioid use
among pregnant women. In 2015, NSDUH, broadened the list of prescription drugs to
include 38 opioid medications (SAMHSA, 2015). Incorporating this new survey
expansion, Marie, Coleman, Vignato, Arndt, & Segre, (2020) examined the use and
misuse of prescription opioids by pregnant and nonpregnant women within the NSDUH
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2015 to 2016. Maire et al. (2020) showed that race particularly white women were most
likely to use opioids. These studies and no others using NSDUH data have identified
barriers and facilitators to opioid treatment use among pregnant and nonpregnant women
who misuse opioids.
To address this gap the purpose of this study is to identify barriers and facilitators
related to opioid use treatment and recovery services among pregnant and nonpregnant
women who misuse opioids. The specific aims of the study are to (1) describe
demographic characteristics (age, race/ethnicity, education, marital status, health
insurance, employment, income, geographic location, and treatment setting), clinical
characteristics (health status, mental health status, and substance use), and opioid use
treatment and recovery services among pregnant and nonpregnant women who misuse
opioids, (2) examine the relationships among demographic characteristics, clinical
characteristics, perceived need for treatment, and facilitators/barriers to opioid use
treatment and recovery services among pregnant and nonpregnant women who misuse
opioids, (3) identify factors associated with increased odds of opioid use treatment and
recovery services among pregnant and nonpregnant women who misuse opioids.
Theoretical Model
The theoretical model underpinning the study is Andersen’s Behavioral Model of
Health Service (1995). Andersen’s (1995) model proposes people seek health services as
a function of three components; (1) predisposing characteristics, (2) enabling or impeding
factors, and (3) perceived need to seek professional help. Anderson (1995) defines
predisposing characteristics as age, gender, education, occupation, ethnicity. Secondly,
enabling factors are classified as community and personal resources for instance
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geographic location, income, and health insurance. Thirdly, the need for care is described
as the person’s view of their own general health and functional state, as well as how they
experience symptoms of illness, pain, and worries about their health and whether or not
they judge their problems to be of sufficient importance and magnitude to seek
professional help. Wu et al. (2016) utilized Andersen’s Behavioral Model of Health
Service when examining treatment utilization among persons with opioid use disorders in
the United States. The relationships of the predisposing characteristics of age, sex, and
race/ethnicity and enabling variables of insurance, income, and population density were
used to organize correlates of receipt of opioid use treatment (Wu et al., 2016). This
study and the knowledge of the following factors; middle age, white race, low income,
non-metropolitan residence, mental health problems, and other substance use disorders
are positively associated with deaths due to opioid overdose (Paulozzi, 2012; and Rudd et
al., 2016) informed the decision to use Andersen’s Behavioral Model of Health Service.

Figure 1. Andersen’s Behavioral Model of Health Service (1995) reprinted from
Revisiting the Behavioral Model and Access to Medical Care: Does it Matter? R.
Andersen. Journal of Health and Social Behavior, 36(1), 1-10.
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Conceptual Framework
The conceptual framework for this study is depicted in Figure 2. The independent
variables identified as demographic characteristics (age, race/ethnicity, education, marital
status, health insurance, employment, income, geographic location, and treatment
setting), clinical characteristics (health status, mental health status, and substance use),
perceived need for treatment, and barriers to treatment. The dependent variable of
treatment use aligns with the concepts of (1) predisposing characteristics (2) enabling or
impeding factors, and (3) perceived need to seek professional help.

Figure 2. Conceptual Model
Implications for Nursing Science
The findings of this study will inform care providers and policy makers about the
characteristics of pregnant and nonpregnant women who misuse opioids that increase the
likelihood of them seeking treatment thus preventing death due opioid overdose and harm
to unborn children. Many actions taken to mitigate the opioids crisis do not specially
address the needs of pregnant women who misuse opioids, but rather address the general

7
public. Research is needed to clarify reasons pregnant and nonpregnant women seek
opioid use treatment.
CHAPTER II
Review of the Literature
Background
According to the CDC (2019) opioids are defined as “natural or synthetic
chemicals that interact with opioid receptors on nerve cells in the body and brain and
reduce the intensity of pain signals and feelings of pain” (para1.) Similarly, Sharma,
Bruner, Barnett, and Fishman (2016) define the term “opioids” as encompassing a class
of drugs, both natural alkaloid compounds derived directly from the resin of the opium
poppy for example heroin, as well as, related synthetic compounds including, oxycodone
and hydromorphone. Opioids are recognized by a variety of names including opiates,
opioids, and narcotics. The term opiates are used for close relatives of opium such as
codeine, morphine and heroin, while the term opioids are used for the entire class of
drugs including synthetic opiates such as Oxycontin and Fentanyl (CDC, 2019).
Opioids act primarily on three receptor types in the nervous system: mu, kappa,
and delta receptors (Brady, McCauley, & Back, 2016). All members of the opioid drug
class share common pharmacological features as agonists of the mu opioid receptor
(Sharma et al., 2016). The mu receptor is primarily responsible for the analgesic and
euphoric properties of opioid. The primary reason for prescribing opioids is to treat
individuals experiencing moderate to severe pain often after receiving surgery, or to treat
cancer (CDC, 2017c). In addition to understanding the mechanism of action and reason
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for prescribing opioids, is it noteworthy to reflect upon the historical influences leading
up to the present-day opioid crisis.
Historical Influences of the Opioid Crisis
The opium poppy plant has been documented as a medicinal plant as early as
3400 B.C. in southwestern Asia (“The Opium Kings”, 1998). During this time the
Sumerians referred to the opium poppy as the “joy plant” and the plant’s euphoric effects
soon spread to the Assyrians, Babylonians, and Egyptians (“The Opium Kings”, 1998). In
460 B.C, Hippocrates acknowledged the opium poppy as a narcotic and mechanism to
stop bleeding in treating medical conditions and epidemics.
The 1600s-1800s
In the 1600-1800s opium was traded throughout Persia, India, China, England,
and the United States (“The Opium Kings”, 1998). In the early 1800s the chemical
properties of morphine, codeine, and thebaine from the opium poppy were identified and
in 1827, E. Merck & Company of Darmstadt, Germany, commercially manufactured
morphine (“The Opium Kings”, 1998). In 1840, New Englanders brought 24,000 pounds
of opium into the United States. This event, influenced the U.S. Customs to put a duty on
the import and in 1890 the U.S. Congress, imposed a tax on opium and morphine (“The
Opium Kings”, 1998). From 1861-1865, medics in the Civil war used morphine to treat
pain, and many soldiers became dependent on morphine (“Opioid Crisis Fast Facts”,
2018).
The 1900s-1920s
In various medical journals during 1902, physicians discussed the side effects of
using heroin as a morphine step-down cure (White & Callahan, 2014). Physicians
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suggested their patients suffered from heroin withdrawal symptoms equal to morphine
addiction (“The Opium Kings”, 1998). In 1903, heroin addiction rose to alarming rates;
leaving 1 in 200 Americans addicted to heroin (White & Callahan, 2014). In 1905 the
U.S. Congress banned opium (“The Opium Kings”, 1998), and in 1906 the U.S. Congress
passed the Pure Food and Drug Act requiring contents labeling on patent medicines by
pharmaceutical companies (“The Opium Kings”, 1998). As a result, the availability of
opiates and opiate consumers significantly declines. The first federal drug prohibition
passes in the U.S. outlawing the importation of opium, 1909. The Harrison Narcotic Act
of 1914 taxed and regulated the sale and distribution of opium and cocaine-based
products requiring physicians and pharmacists, who handled opium and cocaine to
register with the US Department of the Treasury (“Opioid Crisis Fast Facts”, 2018).
According to McCarty, Priest, and Korthuis (2018) the Treasury Department interpreted
the statute as a prohibition against physicians prescribing narcotics to treat patients with a
narcotic addiction. In 1923 the U.S. Treasury Department's Narcotics Division (the first
federal drug agency) banned all legal narcotics sales. With the prohibition of legal venues
to purchase heroin, individuals with an addiction to heroin were forced to buy from
illegal street dealers (“The Opium Kings”, 1998). Arrest and incarceration replaced
clinical services as the preferred intervention for drug use and addiction. Between 1919
and 1924 physicians in 44 communities who operated morphine maintenance clinics, had
them closed under threat of federal indictment (White & Callahan, 2014). This action
lead to a booming black market in New York’s Chinatown (“The Opium Kings”, 1998).
The 1930s-1940s
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During the 1930s most of illegal heroin smuggled into the U.S. came from China
(Sacco, 2014). According to “The Opium Kings” (1998) in 1945, Burma gained
independence from Britain at the end of World War II and opium cultivation and trade
flourished. Another fact to note is resulting from the Great Depression of 1930s, the
budget for the Federal Bureau of Narcotics (FBN) and number of narcotic officers were
low. Moreover, marijuana was on the rise and being used recreationally. This drug was
legal up until the passing of the Marijuana Tax Act of 1937 (Sacco, 2014). All states
followed the Marijuana Tax Act of 1937 and banded the use of marijuana; thus, laying
the foundation for criminalizing people with addiction disorders. For example, Henry
Anslinger, the first commissioner of the FBN, informed Congress “the major criminal in
the United States is the drug addict; of all the offenses committed against the laws of this
country, the narcotic addict is the most frequent offender” (Sacco, 2014, p 3).
The 1950-1970s
In the 1950s, the US. efforts to contain the spread of Communism in Asia
involved forging alliances with tribes and warlords (“The Opium Kings”, 1998). The U.S.
and France supplied the drug warlords and their armies with ammunition, arms, and air
transport for the production and sale of opium. This resulted in an explosion in the
availability and illegal flow of heroin into the United States and into the hands of drug
dealers and addicts (“The Opium Kings”,1998). Between 1965-1970 the U.S.
involvement in Vietnam was blamed for the surge in illegal heroin being smuggled into
the States (“The Opium Kings”,1998). The number of heroin addicts in the U.S. reached
an estimated 750,000 (Sacco, 2014). In 1963, the president’s commission on Narcotic and
Drug Abuse shifted its focus to support a medical approach for the treatment of addiction
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and at the same time methadone maintenance became acceptable. Congress agreed with
the president’s commission and created a Bureau of Drug Abuse Control within the
Department of Health and Education, but there remained a strong emphasis on law
enforcement (Sacco, 2014). In 1968, the Bureau of Narcotic Control merged with the
Federal Bureau of Narcotics and transferred to the Dept of Justice (Sacco, 2014). In
1970, President Nixon called for the “War on Drugs”, placing greater emphasis on law
enforcement as the primary strategy to address the heroin problem. The Controlled
Substances Act (CSA) of 1970, (Title II of the Comprehensive Drug Abuse Prevention
and Control Act) established federal U.S. drug policy on regulating the manufacture,
importation, possession, use, and distribution of certain substances (Sacco, 2014).
According to Christie, Baker, Cooper, Kennedy, and Madras (2017), the CSA was the
national legislation for implementing the Single Convention on Narcotic Drugs.
President Nixon created the Drug Enforcement Administration (DEA) governed under
the Justice Department in 1973 to consolidate all federal powers of drug enforcement in a
single agency (Sacco, 2014). The DEA, the enforcement branch of the CSA, was charged
with registration of physicians, strict annual production quotas, chain-of-custody, and
other regulatory oversight (Sacco, 2014).
The 1980s-1990s
The lack of robust evidence and misinformation. of the addictive properties of
opioids were the catalysts for the present-day epidemic. Two studies set the stage
promoting opioids were safe. Porter & Jick (1980) claimed addiction is rare in patients
treated with narcotics, which fueled the acceptance opioids were safe. Subsequently,
Porter & Jick’s (1980) have been cited in over 600 articles. Additionally, Portenoy &
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Foley’s (1986) retrospectively examined 38 patients with non-malignant pain and
concluded opioids were a more humane and safer treatment then surgery. This false sense
of safety slowly eroded the preexisting knowledge of 1970s that opioids were addictive
(Sacco, 2014).
Pharmaceutical company marketing. Coupled with a sense of safety, the 1990s
brought aggressive marketing campaigns from the Purdue Pharma drug manufacture to
promote the availability of a newer long-acting opioid called Oxycontin (Christie et al.,
2017). Purdue Pharma neglected to reveal the potential abuse and harmful long-term
consequences and are currently being sued (Raymond, 2018). The President’s
Commission Report claims this aggressive promotion of an oxycodone brand, from 19972002, led to a 10-fold growth in prescriptions to treat moderate to severe noncancer pain
and increases in prescribing of other opioids (Christie et al., 2017).
In 2013, providers across the United States wrote a quarter of a billion of opioids
prescriptions (Christie et al., 2017). This number would give every American adult at
least one bottle of opioids. The most commonly prescribed opioids associated with opioid
overdose include, methadone, oxycodone, and hydrocodone (CDC, 2017b). Volkow,
Frieden, Hyde, and Cha (2014) argue 21 to 29 percent of patients prescribed opioids for
chronic pain misuse them. Notably, about 80 percent of people who use heroin, first
misused prescription opioids (Muhuri, Gfroerer, & Davies, 2013).
Pain seen as the 5th vital sign. Other influences leading to the opiod crisis
include pressures in 1995 to treat patients pain and increase the awareness of untreated
pain by external agencies for example, the American Pain Society (Gordon, Dahl, &
Miaskowski, 2005). The phrase, “pain as the fifth vital sign,” was initially promoted by
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the American Pain Society in 1995, to elevate awareness of pain treatment among
healthcare professionals. The Veteran’s Administration and the Joint Commission on
Accreditation of Healthcare Organizations adopted this stance and designated pain as a
‘fifth’ vital sign. Moreover, the Joint Commission, established a quality standard related
to assessing and appropriately treating patient reported pain. This regulation has
increased awareness and pressure for hospitals to meet this standard, as well as being tied
to reimbursement by Medicare through the Value-based purchasing (Christie et al.,
2017).
Physician education & prescribing practice. Additional contributing factors to
the increase of opiod crisis was the lack of physician training on recognizing drug
diversion, addiction, and signs of abuse (Orleans & Kaye, 2017). de Leon-Casasola
(2013) estimates only 20% of US physicians have received training on recognizing
addiction, drug diversion, and signs of abuse. According to Orleans and Kaye (2017) the
pendulum has swung from being reluctant to prescribing to opioids to being excessive
and liberal.
Rise of cheaper illicit drugs. According to the CDC (2017d) the current face of
the opiod crisis includes the drive to purchase illicit drugs such as heroin and synthetic
opioids i.e. fentanyl and analogs, acetylfentanyl, furanylfentanyl, and carfentanil. This
has resulted from the unintended consequence of focused efforts to limit the quantity of
prescription opioids (Christie el al., 2017). Heroin and fentanyl are cheaper than
prescription opioids and unfortunately, Fentanyl is 50 times more potent than heroin and
100 times more potent than morphine. Carfentanil, is estimated to be 10,000 times more
potent than morphine (CDC, 2017d). In 2016, there were more than 19,000 deaths related
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to synthetic opioids (other than methadone) in the United States with the largest increases
in overdose deaths, in males aged 25-44 (CDC, 2017d)
Insufficient prevention and treatment services. Failure to have a standardized
system approach to prevention and treatment has contributed to the current state of the
opioid crisis (Christie, et al., 2017). The American Society of Addiction Medicine
(ASAM) and the Addiction Policy Forum recommended a national public education
campaign, like the one developed for the AIDS epidemic in the 1980s, to raise awareness
that addiction is not a moral failing, but rather a chronic brain disease, and evidencebased treatment is available (Christie et al., 2017, p. 40). Notably, quality treatment
services and the associated workforce did not expand in response to the growing crisis
(Christie et al., 2017). Many states do not cover all levels of care required for effective
treatment, as defined by the American Society of Addiction Medicine criteria.
Stunningly, 85% of all U.S. counties have no Opioid Use Treatment programs that
provide Medication Assisted Treatment (MAT) for people diagnosed with an opioid use
disorder (Christie et al., 2017).
Further widening the treatment gap, is the outdated 1970s Institutions for Mental
Diseases exclusion rule (IMD). This rule prohibits federal funds to be used for Medicaid
patients requiring substance use treatment in residential treatment centers, greater than 16
beds (Nationally Alliance on Mental Illness (NAMI), 2018). These findings highlight the
many state-level disparities in coverage for substance use disorder treatment.
Additional barriers to treatment include the lack of parity of Medicare
beneficiaries receiving inpatient care in psychiatric hospitals. For example, individuals
receiving care for opioid use disorders in psychiatric hospitals are capped to 190 days of
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treatment over their lifetime (National Association of Psychiatric Health Systems, 2013).
Treating mental health care benefits differently from any other medical condition is
discriminatory. The 190-lifetime day restriction does not exist for any other condition
being treated in general hospital.
Essential to slowing this epidemic is improved access to treatment and recovery
services. Unfortunately, according to Collins (2018) 80% of the 2 million Americans with
opioid use disorders do not receive appropriate or adequate treatment for their addiction.
Additionally, there is not a great deal of support to show an increase in access to OUD
services in the last 10 years (Wu, Zhu, & Swartz, 2016). Although the annual National
Surveys on Drug Use and Health (NSDUH) has provided information on risk factors for
OUD related to socioeconomic and demographic factors, few studies have identified
factors related to use of treatment services. Only one study examined the association of
demographics, socioeconomic factors, and behavioral health status with receipt of
treatment (Wu, et al., 2016). Using NSDUH data 2005 to 2013, they found opioid
treatment use varied from 24% with opioid dependence to 5% for those with opioid
abuse. Blacks and Native Hawaiians had substantially decreased odds to accessing
treatment and older age up to age 49 showed increased odds of treatment. This study
showed no difference in treatment by gender.
At the federal level, the Department of Health and Human Services has
established a framework consisting of 5 elements; strengthening public health
surveillance, advancing the practice of pain management, improving access to treatment
and recovery services, targeting the availability of distribution of overdosing reversal
drugs, and supporting research (U.S. Department of Health & Human Services, n.d.)
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Several federal agencies have focused efforts underneath one or more of these 5
strategies. For example, the National Institutes of Health (NIH) National Institute on
Drug Abuse (NIDA) is focused on providing research support on delivering safe effective
pain management, implementing overdose reversal agents, and developing innovative
opioid medication and technologies (Collins, 2018). The CDC focused on strengthening
public health data and reporting, supporting the prescription monitoring program, and
developing clinical guidelines for using opioids and non-opioids to treat chronic pain
(NIH, 2017). The Food and Drug Administration (FDA) developed an Opioid Policy
Steering Committee to address the following three areas; “(1) lowering overall exposure
to opioid drugs (2) enabling more opportunities for those currently addicted to opioid
drugs to seek MAT that can help them recover; and (3) helping expedite the development
of progressively more-effective abuse deterrent formulations of opioid drugs and nonopioid alternatives for the treatment of pain” (NIH, 2017, par 53). Finally, the Substance
Abuse and Mental Health Services Administration (SAMHSA) has focused efforts on
improving access to treatment, prevention, and recovery services. According to NIH
(2017), SAMHSA administers the Opioid State Targeted Response (STR) grants,
authorized by the 21st Century Cures Act. In 2017, 485 million for the next 2 years were
to be distributed to states to assist in implementing prevention, treatment, and recovery
needs (NIH, 2017). SAMHSA expanded the existing Medication Assisted Treatment for
Prescription Drug and Opioid Addiction grants to six additional states to assist with
advancing utilization of medication assisted treatment for individuals with opioid use
disorder. In addition to expanding funding to states, SAMHSA expanded waiver limits for

17
physicians, nurse practitioners, and physician assistants, to treat up to 275 people (NIH,
2017).
At the state level, several states are addressing the opioids crisis by taking a
public health-oriented approach focusing on building infrastructure. For example, after
passage of Vermont Senate bill 303 in May 2000, permitting methadone treatment in
Vermont, the state of Vermont created an integrated healthcare system for addiction
treatment (Brooklyn & Sigmon, 2017). The state expanded Medicaid coverage to include
buprenorphine and increased the amount of waiver trained providers. The “Hub and
Spoke” Model has increased opiod use disorder treatment capacity, eliminated waiting
lists, increased the number of waivered physicians, and saved the state 6.7 million in
2014 (Brooklyn & Sigmon, 2017).
The state of Virginia created an Addiction and Recovery Treatment Services
(ARTS) Benefit that expanded coverage of substance use disorders for all Medicaid
beneficiaries (Northam, 2018). This comprehensive continuum of addiction treatment
services includes, inpatient detoxification, intensive, outpatient programs, partial
hospitalization, residential treatment, office based opiod treatment, case management, and
peer-support services. Virginia was the 4th state to gain permission form the federal
government to expand Medicaid services to include residential treatment services
(Northam, 2018). Additional results from these measures included, a 51% increase of
individuals (10, 500) treated for opioid use disorders compared to 2016 and one third
decrease of emergency department visits by Medicaid members within a 9-month period
(Northam, 2018). This initiative illustrates the recognition that substance use disorder
treatment extends beyond acute care services.
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Additionally, Kentucky, Massachusetts, Maryland, Ohio, and West Virginia have
addressed the opioid overdose problem by promoting the use of effective Medication
Assisted Treatment (MAT) in the context of their Medicaid expansions (Frank & Glied,
2017). Consequently, states have been able to narrow the access to treatment gap through
expansion of Medicaid services (Frank & Glied, 2017). It is imperative other states
replicate and build upon these strategies, as well as, learn from successful initiatives
conducted internationally.
Historically, United States drug policy was heavily weighted on supporting the
supply side; focusing on the interdiction and eradication of drugs (Sacco, 2014). These
efforts contributed to the lack of infrastructure and fragmented healthcare system of
addiction services. While it is important to understand the historical context of policy
that has shaped our belief system; it is wise to step back and examine the works of others.
For instance, Portugal has created a supportive society in which individuals with
substance use disorders can receive treatment for their addiction without the fear of being
prosecuted (Greenwald, 2009). Since 2001, Portugal transitioned from a society of
criminalization to one that provides treatment and supports harm reduction strategies for
individuals with substances use disorders. Individuals with possession of any drug have
72 hours to appear in front of a commission to determine the course of action
(Greenwald, 2009). Through an administrative process, individuals are evaluated to
identify if their actions are related to trafficking a drug or are they requiring treatment for
a substance use disorder. This public health-oriented approach has resulted in a 17%
reduction of new drug-related cases of HIV between 1999 & 2003 (Greenwald, 2009).
The number of Hepatitis C and B in treatment centers were reduced and the total number
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of drug-related deaths decreased from the predecriminalization year of 1999
(approximately 400) to 290 deaths in 2006 (Greenwald, 2009).
Opioid Use Disorder during Pregnancy
The CDC (2019) defines drug misuse, “as the use of illegal drugs and/or the use of
prescription drugs in a manner other than as directed by a doctor, such as use in greater
amounts, more often, or longer than told to take a drug or using someone else’s
prescription”.
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition describes
opioid use disorder as a “problematic pattern of opioid use leading to problems or
distress, with at least two of the following occurring within a 12-month period”
(American Psychiatric Association, 2013, p. 541.)

1. Taking larger amounts or taking drugs over a longer period than intended.
2. Persistent desire or unsuccessful efforts to cut down or control opioid use.
3. Spending a great deal of time obtaining or using the opioid or recovering from its
effects.
4. Craving, or a strong desire or urge to use opioids
5. Problems fulfilling obligations at work, school or home.
6. Continued opioid use despite having reoccurring social or interpersonal problems.
7. Giving up or reducing activities because of opioid use.
8. Using opioids in physically hazardous situations.
9. Continued opioid use despite ongoing physical or psychological problem likely to
have been caused or worsened by opioids.
10. Tolerance (i.e., need for increased amounts or diminished effect with continued
use of the same amount).
11. Experiencing withdrawal (opioid withdrawal syndrome) or taking opioids (or a
closely related substance) to relieve or avoid withdrawal symptoms.

h Maternal Adverse Outcomes Related to OUDs
The impact of OUDs among pregnant women can be devasting to the mother and
neonate (American College of Obstetricians and Gynecologists, 2017). Maeda et al.
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(2016) analyzed 2007-2011data from the Nationwide Inpatient Sample (NIS) of the
Healthcare Cost and Utilization Project sponsored by the Agency for Healthcare Research
and Quality with the focus of examining trends in maternal outcomes with opioid abuse
and dependence. Results revealed within a sample of 20,517,479 delivery admissions
with and without opioid abuse or dependence, participants with opioid abuse or
dependence were white, older in age, insured by Medicaid, and had significantly higher
rates of depression, anxiety, HIV infection, tobacco use, alcohol, or other illicit drug use,
chronic anemia, and previous cesarean delivery (p <.01 for all) when compared with
those without an opioid abuse or dependence. Furthermore, participants with opioid
abuse or dependence during pregnancy had increased odds of obstetrical morbidity and
mortality, including in-hospital mortality (adjusted odds ratio [aOR], 4.6; 95% CI, 1.8 to
12.1), maternal cardiac arrest (aOR, 3.6; 95% CI, 1.4 to 9.1), intrauterine growth
restriction (aOR, 2.7; 95% CI, 2.4 to 2.9), placental abruption (aOR, 2.4; 95% CI, 2.1 to
2.6), length of stay more than 7 days (aOR, 2.2; 95% CI, 2.0 to 2.5), preterm labor (aOR,
2.1; 95% CI, 2.0 to 2.3), oligohydramnios (aOR, 1.7; 95% CI, 1.6 to 1.9), transfusion
(aOR, 1.7; 95% CI, 1.5 to 1.9), stillbirth (aOR, 1.5; 95% CI, 1.3 to 1.8), and premature
rupture of membrane (aOR, 1.4; 95% CI, 1.3 to 1.6) (Maeda et al., 2016). Sutter et al.
(2017) argue behaviors associated with OUDs among pregnant women places them at
greater risk for skin infections related to intravenous drug use, hepatitis C and human
immunodeficiency virus (HIV) from needle sharing and contracting sexually transmitted
diseases. Almario, Seligman, Dysart, Berghella, and Baxter (2009) reported similar
findings of higher percentages of infectious disease among the participants in their study
of 258 opiate addicted gravid women treated with methadone. The most prevalent
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infection was Hepatitis C Virus 53.5% (n=138). The percentage of HIV was 4.3% (n=
11), which was much higher than the estimated prevalence of HIV in the United States at
(0.4%). Their main finding was preterm birth among women with OUDs being treated
with methadone (29.1%) was nearly 3 times the national average for singleton
pregnancies (11.1%) in the United States.
Neonatal Adverse Outcomes Related to OUDs
NAS is a clinical condition in which a neonate experiences various levels of
irritability, temperature dysregulation, poor feeding, failure to thrive, and seizures due to
the abrupt discontinuation of intrauterine exposure to opioids used by the mother during
pregnancy (Kaltenbach et al., 2012; Kocherlakota, 2014). Patrick, Davis, Lehmann, and
Cooper (2015) conducted a retrospective cross-sectional analysis, using discharge data
from the Kids’ Inpatient Database (KID) for 2009 and 2012 and from the Nationwide
Inpatient Sample (NIS) for 2010 and 2011. Results indicated infants with NAS were
more likely than other hospital births to have the following complications, low
birthweight (24.4% vs. 7.2%), transient tachypnea of the newborn (11.7% vs. 3.1%),
meconium aspiration syndrome (2.8% vs. 0.4%), respiratory distress syndrome (4.5% vs.
2.0%), jaundice (32.8% vs. 19.1%), feeding difficulty (17.3% vs. 3.0%), seizures (1.4%
vs. 0.1%), and possible sepsis (14.8% vs. 2.2%; p<0.001). Infants with NAS were also
more likely than other hospital births to be insured by Medicaid (81.5% vs. 46.4%;
p<0.001 (Patrick et al., 2015).
Barriers to Treatment for Pregnant Women with OUDs
The gold standard for treating pregnant women with OUDs is opioid agonist
therapy, also known as medication-assisted treatment, with methadone or buprenorphine
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in conjunction with a comprehensive program of obstetrical care and behavioral
intervention (Klaman et al., 2017). Supporting the gold standard is research from a
landmark study known as MOTHER (Maternal Opioid Treatment: Human Experimental
Research (Jones et al., 2010). MOTHER is a multi-site international randomized
controlled trial comparing methadone and buprenorphine treatment in opioid dependent
pregnant women. This study involved 175 pregnant women with opioid dependency
between 18 and 41 years with a singleton pregnancy. Gestation was between 6 and 30
weeks. One hundred and thirty-one participants completed the study defined as giving
birth while receiving the double-blind study medication either methadone or
buprenorphine. Primary findings showed neonates exposed to buprenorphine required
89% less morphine than did neonates exposed to methadone (mean total doses of 1.1 mg
and 10.4 mg, respectively; P<0.0091 and spent, on average, 43% less time in the hospital
(10.0 vs. 17.5 days, respectively; P<0.0091). Of note, Jones et al. (2010) point out the
superiority of buprenorphine over methadone did not result in differences in the number
of neonates requiring NAS treatment, peak NAS score, head circumference, any other
neonatal outcome, or any maternal outcome; however it clearly shaped the path for
buprenorphine to be used as an alternative to methadone for the treatment of opioid
dependency during pregnancy.
Despite the compelling evidence of how to treat pregnant women with OUDs,
barriers exist for receiving adequate treatment. These include limited access to gender
specific treatment, stigma, provider bias, and fear of legal consequences (Saia et al.,
2016). Many women who are in caregiving roles often will not seek treatment or do not
complete treatment because they are unable to manage their caregiving responsibilities
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and participate in treatment programs at the same time (Saia et al., 2016). Other concerns
include fear their children will be removed from their custody (Angelotta, Weiss,
Angelotta, & Friedman, 2016). NSDUH data from 2005-2014 of non-medical opioid use
among pregnant women found a prevalence of 5% (Kozhimannil, Graves, Levy, &
Patrick, 2017). Depression and anxiety were major risk factors for non-medical opioid
use indicating two potential screening strategies for prevention. Kozhimannil et al.
(2017) found prior alcohol, tobacco, and marijuana use independently predicted nonmedical opioid use among pregnant women; however, this study and no others using
NSDUH data have identified facilitators and barriers to opioid treatment use among
pregnant women.
Chapter III
Methods
The purpose of the study is to identify barriers and facilitators to opioid use
treatment and recovery services among pregnant and nonpregnant women who misuse
opioids. In this chapter a description of the design, sample, data collection, and analytic
techniques is presented. The protection of human subjects and study limitations are also
addressed.
These research questions for this investigation include: Among pregnant and
nonpregnant women who misuse opioids;
1. What are the demographic and clinical characteristics and opioid use treatment
and recovery services?

24
2. What relationships exist among demographic and clinical characteristics,
perceived need, and facilitators/barriers to opioid use treatment and recovery
services?
3.What factors are the most likely to contribute seeking opioid use treatment and
recovery services?
The research questions will be answered through the following aims.
Specific Aims:
Aim I. Describe the demographic characteristics (age, race/ethnicity, education,
marital status, health insurance, employment, income, geographic location,
and treatment setting), clinical characteristics (health status, mental health
status, and substance use), and opioid use treatment and recovery services
among pregnant and nonpregnant women who misuse opioids.
Aim II. Examine the relationships among demographic and clinical
characteristics, perceived need for treatment, and facilitators/barriers to
opioid use treatment and recovery services among pregnant and
nonpregnant women who misuse opioids.
Aim III. Identify factors associated with increased odds of opioid use treatment
and recovery services among pregnant women who misuse opioids.
Research Design
A cross-sectional correlational design was used for this study. The focus of the
study was to analyze data retrospectively collected from the 2016 to 2018 NSDUH to
identify barriers and facilitators to opioid use treatment and recovery services among
pregnant and nonpregnant women who misuse opioids. It is considered cross-sectional
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because the independent and dependent variables were collected at single points in time
(Polit & Beck, 2017).
Sample Cases
The study sample consisted of (n=122) pregnant women who misuse opioids and
(n=3305) of nonpregnant women who misuse opioids. Opioids included heroin and 38
prescription pain relivers. Misuse is defined as ever, even once, used any prescription
pain reliever in any way a doctor did not direct you to use it including; using it without a
prescription of your own; using it in greater amounts, more often, or longer than you
were told to take it, and using it in any other way a doctor did not direct you to use it. as
is of US civilian pregnant women aged 18 and over with OUDs identified within the
NSDUH database during 2016 to 2018.
Inclusion criteria. US civilian, non-institutionalized pregnant and nonpregnant
women aged 12 to 49 years of age who misused opioids within the past year. This
includes pregnant and nonpregnant women living in shelters, rooming houses,
dormitories, migratory workers' camps, halfway houses, as well as, civilians living on
military bases.
Exclusion criteria. US civilian, non-institutionalized pregnant and nonpregnant
women who misuse opioids aged 12 to 49 years of age who are homeless, do not use
shelters, military personnel on active duty, or residents of institutional quarters, i.e. jails
and hospitals were excluded from the study.
Data Source
The NSDUH is an annual survey sponsored by SAMSHA, an agency of the UD
Department of Health and Human Services. Since 1971, data were collected on substance
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use patterns and behaviors among non-institutionalized US civilians in order to inform
public policy and monitor substance use trends (NSDUH, 2018b). RTI International, a
contracted organization with offices based in the US and internationally conducts the
annual data collection (RTI International, 2015).
Sample Size & Configuration
The 2016 and 2017 NSDUH datasets have approximately 4500 pregnant women.
In order to calculate the sample size of the subgroup of pregnant women with OUDs, a
calculation of 5% was applied. This estimate was based upon 5% of pregnant women
with OUDs calculated in the 2005-2014 NSDUH datasets by Kozhimannil et al. (2017).
An estimated sample size of 225 was used to estimate the effect size. The effect size was
calculated using a G-Power calculation with 80% power, two-tailed significance level of
0.05, and sample size of 225. The effect size expressed in an odds ratio is expected to be
1.62 or higher. There is no consensus on the approach to compute the power and sample
size with logistic regression; although Katz (2006) suggests, ten cases for each
independent variable is appropriate. A minimum of 20 cases per variable should be used
to overcome variability in frequencies. In logistic regression an estimate of the
probability of a certain event occurring is made, rather than detecting the difference or
relationship that may be present, such as in linear regression. No assumptions are made
about the dependent variable (Munro, 2005). Unfortunately, the number of pregnant
women who misused opioids in this study was 122; therefore, limiting the ability to
sufficiently power the study need to run a logistic regression.
Measurement
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Table 1. Variables and Operational Definitions
Variable Name

Operational Definition
(as defined by the National Survey on Drug Use and Health
Dataset 2016 to 2018)

Opioid Use Treatment
and Recovery
Services (Dependent
variable)

Self-report of treatment or counseling designed to help reduce
or stop heroin and prescription pain relivers misuse. Includes
detoxification and any other treatment for medical problems
associated with your heroin and prescription pain relivers misuse
use. Included currently receiving treatment and or received
treatment in the past 12 months.

Demographic
(Independent Variable
IV): Age, Race,
Ethnicity, Education,
& Marital status,
Pregnancy

Age: Groups 12-17, 18-25, 26-34, 35-49
Race/Ethnicity: Non-Hispanic White, Non-Hispanic Black or
African American, Non-Hispanic American Indian or Alaska
Native, Non-Hispanic Native Hawaiian/other Pacific Islander,
Non-Hispanic Asian
Education: Less than high school, some college credit, no degree,
associate degree, college graduate or higher.
Marital Status: married, widowed, divorced, or separated,
never been married
Pregnancy: Yes or No

Demographic (IV):
Health insurance,
income, employment,
geographic location of
the US, and treatment
setting

Health insurance: Yes, includes Medicare, Champus, Private health
insurance, other health insurance
Income: Less than 20,000, 20,000-49,999, 50,000-74,999,75,000
or more
Employment: employed full time, employed part time, unemployed,
other
Geographic Location of the US: small, large, non-metro county area
Treatment setting:
Hospital overnight inpatient
Residential Drug/alcohol rehabilitation facility overnight
Drug or alcohol rehabilitation facility outpatient
Mental health center or facility outpatient
Emergency Room
Private doctor’s office
Prison or jail
Self-help group, Alcoholic/Narcotics Anonymous
Other place
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Home, family, friends
Counselor, therapist, psychologist, psychiatrist
Court-mandated/sponsored program
Methadone clinic/program
Name of facility given
Faith based formal program/facility
Clinic, type unspecified

Barriers to treatment
(IV)

Yes=Couldn’t afford - no health care coverage
Treatment not covered on health care
No transportation, too far away, not convenient
Treatment not found for type wanted
No openings in the programs
Didn’t know where to get treatment
Treatment might cause neighbors to have negative opinion
Treatment might have negative effect on job
You didn’t have time (job, childcare, or other comment)
Didn’t want others to find out you needed treatment
Some other reason or reasons

Perceived need for
treatment (IV)

Yes=need treatment for use of heroin past 12 months or prescription
pain relievers past 12 months

Clinical
Characteristics
(Mental Status) (IV)

Serious psychological distress indicator past month (Kessler 6 total
score in past month > =13)
Major Depressive Episode Past Year
Suicide Thought: seriously thought about killing self in the past year
Suicide Plan: made plans to kill self in past year
Suicide Attempt: attempted to kill self in past year

Clinical
Characteristics
(Health Status) (IV)

Self-report of ever been told to have Hepatitis B/C and HIV/AIDS

Clinical
Characteristics
(Substance Use)

Tobacco Use Past Month and Past Year
Alcohol Use Past Month and Past Year
Tobacco Use Past Month and Past Year
Cocaine Use Past Month and Past Year

Marijuana Use Past Month and Past Year
RTI International Data Collection
For the ongoing national study, stratified random sampling by state including the
District of Columbia and household address are used. After consent is obtained
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professional interviewers from RTI International conduct the face-to- face interviews
within the participant’s dwelling. Audio computer assisted self-interviewing and
computer assisted personal interviewing is offered to the participants and their answers to
the questions are entered into a laptop computer provided by the interviewer. Participants
are provided a $30 incentive for completing the survey. Access to the previously collected
data is available for download on the SAMHSA website.
Data Analysis Plan
First, descriptive statistics using the Statistical Package for the Social Sciences
were computed to describe the variables. Frequencies and percentages were calculated to
describe (Aim #1); the demographics & clinical characteristics, perceived need for
treatment, barriers to treatment & treatment use among pregnant women with OUDs.
Bivariate analysis using Chi-squared were calculated to examine the association and
strength of the relationships between the variables of Aim #2, which is to examine the
relationship between treatment use among pregnant women with OUDs, demographics,
clinical characteristics, perceived need for treatment, and barriers to treatment. Upon
completion of the bivariate analysis, it was determined that Aim #3; to identify the odds
of treatment use among pregnant women who misused opioids as accounted for
demographic and clinical characteristics, perceived need for treatment, and barriers to
treatment could not be performed due to a small sample size, n=122.
Protection of Human Subjects
Data collected from the NSDUH Survey is kept confidential by SAMHSA and RTI
International, a contracted third party who conducts the NSDUH Survey. Both parties
abide by the Confidential Information Protection and Statistical Efficiency Act of 2002,
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which under federal law protects the confidentiality of participants responses. All
researchers and project staff are required to sign a confidentiality agreement.
Furthermore, the full names of the participants are not collected nor are associated with
actual addresses (NSDUH, n.d.). Survey data published on SAMHSA public websites do
not have individual participant identifying data. Additionally, the study was submitted,
reviewed, and approved by the Institutional Review Board of the University of San Diego
(See Appendix).
Summary
The focus of this cross-sectional retrospective study was to analyze retrospective
data collected, 2016 to 2018 (NSDUH) to identify barriers and facilitators to opioid use
treatment and recovery services among pregnant and nonpregnant women who misuse
opioids. Study participants include US civilian, non-institutionalized pregnant and
nonpregnant women aged 18 to 49 years of age who misuse opioids living in shelters,
rooming houses, dormitories, migratory workers' camps, halfway houses, as well as,
civilians living on military bases. Independent variables consist of demographic and
clinical characteristics, perceived need for treatment, and barriers to treatment. The
dependent variable is opioid use treatment and recovery services. The findings of this
study will inform care providers and policy makers about the characteristics of pregnant
and nonpregnant women who misuse opioids. This knowledge will assist them provide
treatment, thus preventing death due opioid overdose and harm to unborn children.
Chapter Ⅳ
Results

31
The purpose of the study is to identify facilitators and barriers related to opioid
use treatment and recovery services among pregnant and nonpregnant women who
misuse opioids. The results are presented in this chapter in accordance with the related
research questions and specific aims.
Demographic Characteristics of Study Sample
Research Question #1
What are the demographic and clinical characteristics, and opioid use treatment
and recovery services among pregnant and nonpregnant women who misuse opioids.
Table 2 and 3 address the specific aim #1 of describing the demographic characteristics
(age, race/ethnicity, education, marital status, employment, health insurance, income,
geographic location, and treatment setting), clinical characteristics (health status, mental
health status, and substance use), and opioid use treatment and recovery services among
pregnant and nonpregnant women who misuse opioids.
Within the National Survey for Drug Use and health between 2016 to 2018, a total
of 3427 women misused opioids. One hundred and twenty-two of these women identified
as being pregnant at the time of the survey. Out of the 122 pregnant women who misused
opioids, 54.9% ranged in age from 18-25 years of age and 64.8% were non-Hispanic
white. These findings were similar among nonpregnant women who misused opioids.
Forty percent were between 18- 25 years old and 59.8 % identified as non-Hispanic
white. The majority of both groups work full time, earning between $20,000 and $49,000
per year, and never been married (Table 2). Noted differences, include, 31.1% of pregnant
women who misused opioids completed high school or had a GED whereas only 21.1%
of the nonpregnant women completed high school or have a GED. Furthermore, of those
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pregnant women who misused opioids, 41% live in small metro areas of the united states,
whereas 43% of the nonpregnant women live in large metro areas. Interestingly, 93% of
pregnant women and 85 % of nonpregnant women who misused opioids in the sample
had some form of health insurance that included either Medicare, Medicaid/CHIP,
Champus, or private health insurance.
With regards to treatment settings, of those women who sought treatment and
recovery services for opioids, 20% of pregnant women and 67% of nonpregnant women
who misused opioids obtained treatment in either at an outpatient mental health center or
facility while 33% of pregnant women and 23.5 % of nonpregnant women who misused
opioids went to an outpatient drug or alcohol rehabilitation services. Only 15 pregnant
women who misused opioids responded to the question of received and or currently
receiving treatment for misusing opioids and 311 nonpregnant women who misused
opioids responded to this question.

Table 2. Demographic Characteristics of Pregnant and Nonpregnant Women Who
Misused Opioids in the last year.
Characteristics

Age
12-17 Years Old
18-25 Years Old
26-34 Years Old
35-49 Years Old
Race/Ethnicity
White
Black/African American
Native American/Alaska
Native
Native HI/Other Pac Isl
Asian
More than one race
Hispanic
Education

Total Sample

(n) 3427 %

Pregnant Women
Misusing Opioids in
last Year
(n) 122
%

Nonpregnant Women
Misusing Opioids in last
Year
(n) 3305
%

(727)
(1361)
(826)
(513)

29.8
39.7
24.1
14.9

(7)
(67)
(36)
(12)

5.7
54.9
29.5
9.8

(720)
(1294)
(790)
(501)

21.8
39.2
23.9
15.2

(2055)
(387)
(76)

59.9
11.29
2.22

(79)
(11)
(8)

64.8
9.0
6.6

(1976)
(376)
(68)

59.8
11.4
2.1

(20)
(70)
(194)
(625)

0.583
2.04
5.66
18.23

(2)
(0)
(7)
(15)

1.6
0.0
5.7
12.3

(18)
(70)
(187)
(610)

0.5
2.1
5.7
18.5
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<High School
High School/GED
Some College Credit, no
degree
Associates Degree
College Graduate or
Higher
Marital Status
Married
Widowed
Divorced or Separated
Never Been Married
Respondent is <= 14 years
old
Employment
Employed full time
Employed part time
Unemployed
Other
12-14-year old
Income
Less than $20,000
$20,000 - $49,999
$50,000 - $74,999
$75,000 or More
Geographic Location
Large Metro
Small Metro
Nonmetro
Health Insurance
Has Health Insurance
Treatment Setting
Hospital overnight as
inpatient
Residential drug/alcohol
rehabilitation facility
overnight
Drug or Alcohol Rehab
facility as outpatient
Mental Health Center or
Facility as outpatient
Emergency Room
Private Doctor Office
Prison or jail
Self-Help Group,
Alcoholic/Narcotics
Anonymous
Other Place
Home, Family, Friends
Counselor, therapist,
psychologist, psychiatrist

(1076)
(736)
(851)

31.40
21.48
2.36

(28)
(38)
(32)

23.0
31.1
26.2

(1048)
(698)
(819)

31.7
21.1
24.8

(266)
(498)

7.76
14.53

(8)
(16)

6.6
13.1

(258)
(482)

7.8
14.6

(620)
(18)
(279)
(2280)
(230)

18.09
0.52
8.14
66.5
6.71

(32)
(0)
(6)
(82)
(2)

26.2
0.00
4.9
67.2
1.6

(588)
(18)
(273)
(2198)
(228)

17.8
0.52
8.3
66.5
6.9

(1234)
(663)
(359)
(941)
(230)

36.0
19.35
10.47
27.46
6.71

(42)
(18)
(20)
(40)
(2)

34.4
14.8
16.4
32.8
1.6

(1192)
(645)
(339)
(901)
(228)

36.1
19.5
10.3
27.3
6.9

(971)
(1170)
(483)
(803)

28.33
34.1
14.09
23.43

(42)
(44)
(15)
(21)

34.4
36.1
12.3
17.2

(929)
(1126)
(468)
(782)

28.1
34.1
14.2
23.7

(1458)
(1258)
(711)

42.54
36.71
20.75

(38)
(50)
(34)

31.1
41.0
27.6

(1420)
(1208)
(677)

43.0
36.6
20.5

(2927)

85.41

(113)

92.6

(2814)

85.1

(11)

3.37

(2)

13

(9)

2.9

(29)

8.89

(2)

13

(27)

8.7

(78)

23.93

(5)

33

(73)

23.5

(70)

21.47

(3)

20

(67)

21.5

(1)
(54)
(6)
(42)

0.31
16.56
1.84
12.58

(0)
(1)
(0)
(1)

0
6.6
0
6.6

(1)
(53)
(6)
(41)

0.32
17
1.9
13.2

(7)
(2)
(9)

2.15
0.613
2.76

(0)
(0)
(1)

0
0
6.6

(7)
(2)
(8)

2.3
0.64
2.57

Courtmandated/sponsored
Program
Methadone
Clinic/Program
Name of facility/Program
Faith-Based Formal
Program/facility
Clinic-Type Unspecified

(1)

0.307

(0)

0

(1)

0.32

(7)

2.15

(0)

0

(7)

2.3

(6)
(2)

1.84
0.613

(0)
(0)

0
0

(6)
(2)

1.9
0.64

(1)

0.306

(0)

0

(1)

0.32
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Clinical Characteristics of Study Sample
The ACOG Committee on Health Care (2017) claims that opioid dependence
among pregnant women places them at a higher risk to of experiencing HIV, and
Hepatitis B or C. Four out of 36 pregnant women and 89 out of 970 non pregnant women
who misused opioids in the past year reported having Hepatitis B or C. No pregnant
women and 5 out of 970 nonpregnant women who misused opioids reported having HIV
or AIDs (Table 2). Within the past month 29.6% of pregnant women who misused
opioids claim to have a serious mental illness and 23.5% experienced a major depressive
episode with the past year. Thirty-three percent of pregnant women and 24.3 % of
nonpregnant report attempting to end one’s life. Women in this sample report using other
substances in addition to misusing opioids. Marijuana use in past month was reported by
32.8% pregnant and 38.1% nonpregnant women; alcohol use as the next most frequently
reported substance used; 22% for pregnant women and 61.7% for nonpregnant women
(Table 3). Examining treatment variables indicated low frequencies. Thirteen of 122
pregnant women (10.7%) compared to 6.5% of nonpregnant women who misused opioids
received treatment in the last year or are currently receiving treatment; 3.3% of pregnant
women and 1.8% of nonpregnant women perceive they have a need to obtain treatment
for misusing opioids.
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Table 3. Clinical Characteristics of Pregnant and Nonpregnant Misusing Study
Participants.
Characteristics

Total Sample

(n)
Health Status
Hepatitis B or C
HIV or AIDs
Mental Health Status
Serious Psych Distress
Past Month
Major Depressive
Episode Past year
Suicide
Thought
Plan
Attempt
Other Substance Use
Tobacco Past Month
Tobacco Past Year
Cocaine Past Month
Cocaine Past Year
Marijuana Past Month
Marijuana Past Year
Alcohol Past Month
Alcohol Past Year
Treatment
Perceived Need for
Opioid Use Treatment
Barriers to Treatment
Received or Currently
Receiving Treatment for
Opioid Misuse

%

Pregnant Women
Misusing Opioids in last
Year
(n)
%

Nonpregnant Women
Misusing Opioids in last
Year
(n)
%

(1006)
(1006)

9.2
0.49

(4)
(0)

11.1
0

(89)
(5)

9.2
0.5

(2700)

30.3

(34)

29.6

(783)

30.3

(2700)

28.67

(27)

23.5

(747)

28.9

(2675)
(606)
(605)

22.65
43.23
24.62

(24)
(10)
(8)

21.2
41.7
33.3

(582)
(252)
(141)

22.7
43.3
24.3

(3427)
(3427)
(3427)
(3427)
(3427)
(3427)
(3427)
(3427)

47.68
57.16
5.31
15.26
37.93
55.12
60.26
81.70

(62)
(84)
(3)
(17)
(40)
(77)
(27)
(99)

51
68.9
2.5
13.9
32.8
63
22
81

(1572)
(1875)
(179)
(506)
(1260)
(1812)
(2038)
(2701)

47.5
56.7
5.4
15.3
38.1
54.8
61.7
81.7

(3427)

1.87

(4)

3.3

(60)

1.8

(3427)
(3427)

2.62
6.62

(5)
(13)

4.1
10.7

(85)
(214)

2.6
6.5

Research Question #2
What relationships exist among demographic and clinical characteristics,
perceived need for treatment, and facilitators/barriers to opioid use treatment and
recovery services among pregnant and nonpregnant women who misuse opioids?
Specific Aim #2
Examine the relationships among demographic and clinical characteristics,
perceived need for treatment, and facilitators/barriers to opioid use treatment and
recovery services among pregnant and nonpregnant women who misused opioids.
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A bivariate analysis using Chi-squared and Fisher’s Exact tests of association
were conducted on categorical variables (Table 4). Significant associations were noted
with six variables; age (χ2=25.406, df=3, p=<0.001), race/ethnicity (LR=17.721, df=6,
p=<0.007), geographic location (χ2=7.585, df=2, p=<0.023), health insurance
(LR=13.909, df=5, p=<0.016), tobacco use within the past year (χ2=7.058 df=1, p=008),
and alcohol use within the past month (χ2=76.783, df=1, p=<0.001). Health status
variables of Hepatitis B/C and HIV/AIDS, and, mental health status indicators were not
significant (Table 4). Perceived need for treatment, barriers to treatment, and currently
and received treatment for opioid misuse were not significant within this sample of
women.

Table 4. Associations between Demographic and Clinical characteristics, Perceived Need
for Treatment, and Facilitators/Barriers to Opioid Use Treatment and Recovery
Services among Pregnant and Nonpregnant Women Who Misuse Opioids.
Characteristics

Age
Race/Ethnicity
Education
Marital Status
Employment
Income
Geographic location
Health Insurance
Health Status
HEP B/C
HIV/AIDS
Mental Health Status
Serious Psych Distress
Past Month
Major Depressive
Episode Past Year

Pregnant
Women
Misusing
Opioids in
last Year

Nonpregnant
Women
Misusing Opioids
in last Year

Statistical Test

df

p-value

Total (n)
122
122

Total (n)
3305
3305

3
6

<0.001*
.007*

3305
3305
3305
3305
3305
2814

2= 25.406
Likelihood
Ratio17.721
2= 8.895
2= 6.243
2= 5.82
2= 4.173
2= 7.585
Fisher’s Exact Test

122
122
122
122
122
113

4
3
3
3
2

.064
.100
.152
.243
.023*
.018*

36
36

970
970

Fisher’s Exact Test
Fisher’s Exact Test

115

2585

2=.027

1

.868

115

2585

2=1.581

1

.209

.567
1.0
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Suicide Thought
Suicide Plan
Suicide Attempt
Substance Use
Tobacco Past Month
Tobacco Past Year
Cocaine Past Month
Cocaine Past Year
Marijuana Past Month
Marijuana Past Year
Alcohol Past Month
Alcohol Past Year
Treatment
Perceived Need for
Treatment
Barriers to Treatment
Received or Currently
Treatment for Opioids

113
24
24

2562
582
581

2 =.135
2= .025
2= 1.020

1
1
1

.713
.874
.312

122
122
122
122
122
122
122
122

3305
3305
3305
3305
3305
3305
3305
3305

2=.500
2=7.058
2= 2.046
2=.172
2=1.423
2=3.268
2=76.783
2= .026

1
1
1
1
1
1
1
1

.480
.008*
.153
.678
.233
.071
<0.001*
.871

122

3305

Fisher's Exact Test

122
122

3305
3305

Fisher's Exact Test
2= .325

.241
1

.252
.068

*statistical significance ≤ = 0.05

Research Question #3.
What factors are the most likely to contribute to receiving opioids misuse
treatment and recovery services among pregnant women who misuse opioids?
Specific Aim #3.
Identify factors associated with increased odds of opioid misuse treatment and
recovery services among pregnant women who misuse opioids. Unfortunately, the sample
size for pregnant women who misused opioids (n=122) was small and lacked sufficient
power, thus a logistic regression was not conducted. This subgroup of women who
misused opioids, 4 out of 122 (3%) perceived they had a need to receive treatment for
opioids and 13 of 122 (10.7%), 5 pregnant women who misused opioids out of 122
identified barriers to receiving treatment, and 13 of these women actually received or are
currently receiving treatment for opioid misuse. These low frequencies limit the ability
to reliability predict factors associated with increased odds of receiving opioid misuse
treatment.
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Chapter Ⅴ
The purpose of this study was to identify facilitators and barriers related to opioid
use treatment and recovery services among pregnant and nonpregnant women who
misuse opioids. Discussion of study findings, limitations, and implications for nursing
and future research will be examined in this chapter.
Discussion of Findings
Three years of NSDUH data, 2016-2018, indicated 3427 females misused opioids.
Within this group, 122 reported being pregnant at the time of the survey. The following 3
research questions were proposed; (1) What are the demographic and clinical
characteristics, and opioid use treatment and recovery services among pregnant and
nonpregnant women who misuse opioids? (2) What relationships exist among
demographic and clinical characteristics, perceived need for treatment, and
facilitators/barriers to opioid use treatment and recovery services among pregnant and
nonpregnant women who misuse opioids? and (3) What factors are the most likely to
contribute to receiving opioids misuse treatment and recovery services among pregnant
women who misuse opioids? Two out of the three research questions were answered.
Similarities and differences exist between the demographic and clinical
characteristics of the 2 groups of opioid misusing females (pregnant and nonpregnant
women). Both groups had higher frequencies among the 18-25 years of age range group,
as well as, 64.8% of pregnant women misusing opioids and 59.8% of nonpregnant
women identified as non-Hispanic white. These data are consistent with findings from
Kozhimannil et al (2017) who examined 2005-2014 NSDUH data for pregnant women
misusing prescription opioids within the past year and past month. Results included
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63.3 % were less than or equal to 25 years of age and 66.8% were non-Hispanic
Caucasian. Additional like variables between the 2 groups of opioid misusing females,
included, never being married, working full time, and seeking treatment in an outpatient
drug or alcohol rehabilitation. Similar work by Kozhimannil et al. (2017) indicated
70.4% of pregnant women misusing prescription opioids were not married.
Differing demographic characteristics between the 2 groups included level of
education and geographic location. Pregnant women misusing opioids (31.1%) had high
school or a GED whereas 31.7% of nonpregnant women misusing opioids had less than
high school education. In contrast 36.9% of pregnant women misusing prescription
opioids indicated some post-secondary level of education (Kozhimannil et al., 2017).
Furthermore, pregnant women who misused opioids, 41% live in small metro areas of the
united states, whereas 43% of the nonpregnant women live in large metro areas.
Common clinical characteristics of both groups were the presence of serious
psychological distress and the use of additional substances such as cocaine, marijuana,
and alcohol. Significant associations were noted with six variables; age (χ2=25.406, df=3,
p=<0.001), race/ethnicity (LR=17.721, df=6, p=<0.007), geographic location (χ2=7.585,
df=2, p=<0.023), health insurance (LR=13.909, df=5, p=<0.016), tobacco use within the
past year (χ2=7.058 df=1, p=008), and alcohol use within the past month (χ2=76.783,
df=1, p=<0.001).
These results are consistent with Maeda et al. (2016) analysis of 2007-2011data
from the Nationwide Inpatient Sample (NIS) of the Healthcare Cost and Utilization
Project sponsored by the Agency for Healthcare Research and Quality. Results revealed
within a sample of 20,517,479 delivery admissions with and without opioid abuse or
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dependence, participants with opioid abuse or dependence were white, insured by
Medicaid, and had significantly higher rates of depression, anxiety, tobacco use, alcohol,
or other illicit drug use, (p <.01 for all) when compared with those without an opioid
abuse or dependence.
Kozhimannil et al. (2017) found prior past year of alcohol [AOR,1.56; 95% CI,
1.11-2.17], tobacco [AOR, 1.72; 95% CI, 1.17-2.53], and marijuana use [AOR, 3.44;
95% CI,2.47-4.81] use independently predicted non-medical opioid use among pregnant
women. Qato, Zhang, Gandhi, Simoni-Wastila, and Coleman-Cowger (2020) examined
the co-use of alcohol, tobacco, and licit and illicit controlled substances among pregnant
and nonpregnant women in the United States. Their findings revealed determinants of couse among pregnant women to include: younger age, 18–25 years compared to those ≥ 26
years [AOR(95% CI): 1.81(1.18, 2.80)]; lower income (< $30,000 USD annually)
compared to the highest income bracket (≥$50,000 USD) [AOR 1.65(1.09, 2.48)]; and
prior history of substance use [AOR 5.42 (3.59, 8.20)]. They found lower odds of co-use
in Hispanic women compared to white women [AOR 0.54 (0.31, 0.94)]; married versus
unmarried women [AOR 0.54 (0.34, 0.87)]; women with public vs. private insurance
[AOR 0.54 (0.32, 0.89)].
Unfortunately, the ability to determine what factors are most likely to contribute
to pregnant women who misuse opioids receiving opioid use treatment and recovery
services was challenging to ascertain due to small sample size and lack of sufficient
power. Sadly, 10.7% of pregnant women misusing opioids and 6.5 % of nonpregnant
women misusing opioids received or is currently receiving treatment for opioid misuse.
Only 5 out of 122 of pregnant women misusing opioids and 214 out of 3305 of
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nonpregnant women misusing opioids identified barriers to treatment. Barriers for the 5
pregnant women included unable to afford treatment, stigma, lack of time due to
childcare, job, or other commitments, lack openings in treatment program, and or no
transportation. Similar findings were reported by 20 pregnant women receiving opioid
misuse treatment at care facility at John Hopkins (Frazer, McConnell, & Jansson, 2019).
This qualitive study revealed the following barriers to treatment themes: not wanting to
leave children or partner at home, fear of punitive measures or loss of custody, lack of
information about treatment options, concerns about judgement and stigma, and lack of
transportation. The NSDUH 2016-2018 data does not include “fear of losing custody of
child” in the list of options for barriers to treatment. There is evidence that would support
adding this question to future NSDUH surveys. Angelotta et al. (2016) claim fear of
losing custody of children is a barrier for seeking substance use treatment. Of note, 90%
of the participants (n=20) in the Frazer et al. (2019) study were identified as motivated
for treatment and received substance use treatment prior to the study. This population
differs from the NSDUH 2016-2018 sample (n=122). This sample showed only 3.3 % of
pregnant women misusing opioids and 1.8 % of nonpregnant women misusing opioids
perceive they have a need for opioid use treatment. Although these numbers are not
statically significant; recognition of these staggering low percentages and response rates
shine a light on the need to address the issue of perceived need for treatment.
Limitations
Limitations to the study include survey results based on self-report, potentially
creating social-desirability bias. Additionally, the cross-sectional data collection prevents
causal interpretation (Wu et al., 2016) and NSDUH excludes the homeless individuals,
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military personnel on active duty, and residents of institutional group quarters limiting the
generalizability of these populations. Additionally, the sample size of the pregnant
women misusing opioids was too small and lacked sufficient power, thus a logistic
regression was not conducted.
Importance to Nursing Practice, Education and Policy
The maternal and neonatal consequences of not receiving treatment for OUDs is
well known. To address these issues many professional organizations and agencies such
as the American Society of Addiction Medicine (Kampman, & Jarvis 2015), American
College of Obstetricians and Gynecologists (2017) and SAMSHA (2018) have provided
clinical guidelines and recommendations. Additionally, aggregate reports of substance
use during pregnancy are available (SAMSHA, 2016 & CDC, 2018) however, they are
often described in broad terms. Despite these resources, there remains a need to better
understand the demographic and clinical characteristics of pregnant women who misuse
opioids to inform prevention, screening, and treatment efforts (Patrick et al.,2015).
Results from the NSDUH 2016-2018 data indicate a disproportionate amount of 18-25year-old non-Hispanic white misuse opioids during pregnancy. As well, significant
associations between pregnant and nonpregnant women misusing opioids were noted
with age, race/ethnicity, geographic location, health insurance, tobacco use within the
past year, and alcohol use within the past month. Although, not statically significant, it is
clinically important to recognize 3.3 % of pregnant women misusing opioids and 1.8 %
of nonpregnant women misusing opioids perceive they have a need for opioid use
treatment. It is unknown to what effect the lack of perceived need for treatment
contributes to the 10.7% of pregnant women misusing opioids and 6.5 % of nonpregnant
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women misusing opioids receiving treatment in this study. These numbers cannot be
ignored. In conjunction to increasing access to treatment and enhancing clinical
guidelines it is imperative to address the issue of perceived need for treatment. Studies
have shown those who recognize having a problem with substance use and perceive a
need for treatment are more likely to seek help than those who do not (Ali, Teich, &
Mutter, (2015); Choi, DiNitto, & Marti, 2014; & Grella, Gil-Rivas, & Cooper, 2009).
Resources exist to assist healthcare providers assist individuals with low motivation and
lack of perceived need for substance use treatment (SAMSHA , 2019). As a start,
emphasis on motivational interviewing techniques and understanding of the
Transtheoretical Model would be worthwhile in primary care and obstetrical settings.
Policy Recommendations
To outpace the opioid epidemic, it is imperative efforts continue to focus on
comprehensive public health-oriented policies, for example increasing funding for
prevention, treatment, and recovery services instead of increasing funding that penalizes
and criminalizes pregnant women with substance use disorders. Setting the tone with the
correct language; referring to the opioid crisis as a “public-health emergency was a move
in the right direction (Hirschfeld Davis, 2017). Secondly, supporting funding to states in
Opioid State Targeted Response Grants to address prevention, treatment, and recovery
services signals the importance and provides a foundation for much needed infrastructure.
Detoxification alone is insufficient (Sharma, Bruner, Barnett, & Fishman, 2016). The US
Department of Health and Human Services (2018) released $485 million over a 2-year
period as a measure of the 21st Century CURES ACT, however building sustainable
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infrastructure to meet the needs of this population is estimated to take longer and may
need additional funding.
Remove Provider Barriers
Comprehensive treatment for opioid addiction also takes into consideration policy
that continues to remove barriers for physicians, nurse practitioners, and physician
assistants, to treat and prescribe MAT (Kolodny et al., 2015). Currently qualified
providers can apply for a waiver through the SAMSHA that permits them to prescribe
medications up to 275 individuals with opioid use disorders (SAMSHA, 2018). Policy to
expand education on the treatment and prevention of substance use disorders in medical
and nursing training, as well as, education to the public are necessary steps to increase
access and prevent death due to opioid overdose (Christie et al., 2017).
Decriminalization
The final recommendation to curb the opioid crisis is advocating for stronger drug
policy that decriminalizes individuals with opioid use disorders. Supporting this premise
is the American Academy of Nursing (AAN). In 2019, the AAN called to end criminal
prosecution and punitive civil actions to pregnant and parenting women based solely on
their substance use disorder. Countries like Portugal have established decreased drug
related deaths, cases of HIV and Hepatitis B & C (Greenwald, 2009). According to Drug
Policy Alliance (2017) the US has made some movement towards decriminalizing, such
as reducing marijuana possession to a misdemeanor and or legalizing marijuana in some
states; however stronger efforts are needed. Based on an analysis of 1,186,810 national
arrests for drug law violations in 2016: 84.7% (1,004,762) were for possession of a
controlled substance. Only 15.3% (182,048) were for the sale or manufacturing of a drug
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(Drug War Facts, 2018). Moreover, “there are currently 500,000 persons imprisoned in
the U.S. for violating drug laws; this is more than all the prisoners in all the Western
European nations combined, the US federal prison population has grown by 900% since
the Controlled Substances Act was enacted in 1970 (Criminal Justice Policy Foundation,
nd.). According to the Guttmacher Institute (2020), 23 states and the District of
Columbia claim substance use during pregnancy to be child abuse under civil childwelfare statutes, and 3 consider it grounds for civil commitment. Of promise, 19 states
have either created or funded drug treatment programs specifically targeted to pregnant
women, and 17 states and the District of Columbia provide pregnant women priority
access to state-funded drug treatment programs. Individuals with substance use disorders
need treatment and rehabilitation not incarceration.
Conclusion and Implications for Nursing
For women struggling with addiction, the toughest step toward recovery is the
very first one; recognizing that you have a problem and deciding to make a change. MAT
is clinically proven to assist pregnant women recovery from their OUD and reduce
maternal and fetal complications ( Jones et al., 2010). Sadly, over 95% of the pregnant
and nonpregnant women in this study identified as misusing opioids did not perceive they
had a problem. These findings sound the alarm for clinicians to act. It is our
responsibility to equally focus efforts on understanding the construct of perceived need
and help seeking behaviors among pregnant women, as well as, deploy known techniques
to engage them in recovery.
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